Mergers & acquisitions
Enliven Therapeutics and Imara will merge in an all-stock deal to form a precision oncology company. The new entity will operate under the name Enliven Therapeutics.
Verseon has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform. Financial terms were not disclosed.
Last week, rumors spread that PureTech Health was preparing to merge with Nektar Therapeutics. Now the deal, never officially announced, has been called off.
Funding rounds this week saw money flow into innovative drug discovery and delivery platforms, while pharma powerhouse Pfizer wrapped up two high-value neuro deals.
Ginkgo Bioworks opened its wallet Tuesday and snapped up Circularis and Altar to strengthen its cell and gene therapy programs and bolster its manufacturing capabilities.
Incyte Corporation will acquire privately-held Villaris and AmplifyBio will acquire PACT Pharma, while Estrella will gain a spot on the Nasdaq Exchange.
Myovant Sciences formed a special committee of independent directors to assess Sumitovant Biopharma’s offer after Sumitovant announced plans to acquire the company.
AstraZeneca is acquiring LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts to braoden its portfolio in genomics and rare diseases.
Solid Biosciences and AavantiBio – announced Friday they are merging to develop a portfolio of neuromuscular and cardiac programs, initially focusing on Duchenne muscular dystrophy.
Two rare disease companies - Idera Pharmaceuticals and Aceragen - are merging to pursue the common goal of an FDA approval that could come as early as 2024.
PRESS RELEASES